(Repeats to add story keyword used by media customers; No changes to text)
Nov 29 (Reuters) - British drugmaker AstraZeneca Plc said on Friday its cancer drug Imfinzi has been granted a speedy review by the U.S. Food and Drug Administration (FDA) for the treatment of a particularly aggressive type of lung cancer.
The company said the FDA accepted its supplemental application and granted priority review to Imfinzi for the treatment of previously untreated late-stage small cell lung cancer.
A final decision is expected in the first quarter of 2020. (Reporting by Pushkala Aripaka in Bengaluru; Editing by Shounak Dasgupta)